

1 FMT Restores Colonic Protein Biosynthesis and Cell Proliferation in Patients with
2 Recurrent *Clostridioides difficile* Disease

3

4 G. Brett Moreau¹, Mary Young¹, Brian Behm¹, Mehmet Tanyüksel¹, Girija
5 Ramakrishnan¹, and William A. Petri, Jr.^{1,2,3}

6 Departments of Medicine¹, Microbiology, Immunology and Cancer Biology², and
7 Pathology³, University of Virginia, Charlottesville VA 22908

8

9 **Abstract**

10 Recurrent *C. difficile* infection (CDI) is a major health threat with significant mortality and
11 financial costs. Fecal Microbiota Transplantation (FMT) is an effective therapy, however
12 the mechanisms by which it acts, particularly on the host, are poorly understood. Here
13 we enrolled a prospective cohort of human patients with recurrent CDI (n=16)
14 undergoing FMT therapy. Colonic biopsies were collected and bulk RNA sequencing
15 was performed to compare changes in host gene expression pre- and two months post-
16 FMT. Transcriptional profiles were significantly altered after FMT therapy, with many
17 differentially expressed genes (~15% of annotated genes detected). Enrichment
18 analysis determined that these changes were reflective of increased protein production
19 post-FMT, with enrichment of pathways such as Ribosome Biogenesis, Protein
20 Processing, and signaling pathways (Myc, mTORc1, E2F) associated with cell
21 proliferation and protein biosynthesis. Histology of H&E-stained biopsies identified a
22 significant increase in colonic crypt length post-FMT, suggesting that this treatment
23 promotes cell proliferation. Crypt length was significantly correlated with enriched Myc

24 and mTOR signaling pathways as well as genes associated with polyamine
25 biosynthesis, providing a potential mechanism through which this may occur. Finally,
26 signaling pathways upstream of Myc and mTOR, notably IL-33 Signaling and EGFR
27 ligands, were significantly upregulated, suggesting that FMT may utilize these signals to
28 promote cell proliferation and restoration of the intestine.

29

30 **Introduction**

31 *Clostridioides difficile* infection (CDI) is a critical public health threat that is associated
32 with significant morbidity, mortality, and financial costs. Although the CDI-associated
33 mortality rate in the United States is 2.7% for primary infection, there is a 20%
34 recurrence rate (1), and mortality is nearly 10 times higher (25.4%) for recurrent disease
35 (2). While standard of care for CDI remains antibiotic treatment (3, 4), antibiotic
36 exposure is a significant risk factor for recurrent CDI (5) due to its disruption of the
37 intestinal microbiota. Because of this, fecal microbiota transplantation (FMT) has
38 emerged as a major therapeutic option for recurrent CDI. Two FMT therapeutics have
39 recently been FDA-approved for the treatment of recurrent *C. difficile*: SER-109 (Vowst),
40 an oral therapeutic utilizing purified *Firmicutes* spores (6) and RBX2660 (Rebyota),
41 which uses a consortium of live microbes and is delivered via enema (7). As both
42 products are of limited efficacy, better understanding of the specific mechanisms
43 underlying FMT offer the promise for improved treatment.

44

45 Our understanding of the mechanisms through which FMT is protective, particularly its
46 effect on the host, remain incomplete. Because CDI is associated with antibiotics and

47 microbiome disruption (8, 9), much of the work looking at FMT's role in recurrent CDI
48 has focused its impact on restoration of the intestinal microbiota (10) and resulting
49 microbial metabolites, such as bile acids (11–13). These results suggest that FMT may
50 protect against *C. difficile* through niche restriction and competition with the transplanted
51 microbes (14). However, signaling from the microbiota can also affect intestinal immune
52 cell development and signaling (15), and it is likely that FMT also initiates changes in
53 the intestinal epithelium or immune cells that impacts successful protection from
54 recurrent disease. A role for the immune response in the pathogenesis of primary CDI
55 has previously been identified, as elevated immune responses and increased
56 inflammation in response to toxin-mediated tissue damage are associated with worse
57 clinical outcomes independently of bacterial burden (16–18). In addition, the type of
58 immune response can have a significant impact on disease progression, as Type 3
59 immune responses have been associated with exacerbated disease severity (19), while
60 Type 2 immunity has been associated with tissue repair and protection from severe
61 disease (20–22). Based on these data, we hypothesized that FMT directly impacts host
62 responses in the gut to promote protection against recurrent CDI.

63

64 We have recently identified gene expression changes associated with the initial stages
65 of FMT in a mouse model of antibiotic treatment (23). This study found significant
66 changes in host immune responses both transcriptionally and in immune cell
67 populations within one week of FMT administration. FMT was also associated with
68 upregulation of genes associated with intestinal homeostasis and neuropeptide
69 signaling, which suggest that FMT can promote restoration of intestinal homeostasis in

70 the absence of prior *C. difficile* exposure. While the effects of FMT on the host have
71 become better understood, many of these studies have looked in the context of other
72 inflammatory disorders, such as intestinal colitis (24–26). In addition, data in patient
73 cohorts is still limited, as most studies have utilized animal models. Many studies with
74 FMT patients have been limited to the assessment of systemic biomarkers, finding that
75 FMT can alter inflammatory biomarkers (27, 28) as well as miRNA profiles, which can
76 impact immune signaling (29). Both immune and colonic transcriptional changes have
77 previously been characterized by our group in a cohort of patients receiving FMT for
78 recurrent CDI (30). This study observed increased expression of the Type 2 cytokine IL-
79 25 along with increased expression of genes promoting intestinal epithelial cell
80 differentiation and extracellular matrix restoration post-FMT. However, this study was
81 limited by a small cohort size (n=6) and the confounder of IBS-like symptoms in two
82 patients in the study.

83

84 The current study aimed to replicate these findings in a larger patient cohort with a more
85 expansive collection of biological samples, allowing for more thorough characterization
86 of the biological changes associated with FMT. We utilized bulk RNA sequencing of
87 colonic biopsies pre- and two months post-FMT to investigate FMT-driven changes in
88 host transcriptional profiles. Our results suggest that FMT promotes expression of
89 protein biosynthesis and extracellular matrix remodeling pathways, potentially through
90 upstream IL-33 and EGFR signaling. These changes may promote increased cell
91 proliferation within the colon and restoration of intestinal homeostasis.

92

93 **Methods**

94 **Study Enrollment**

95 Participants in this study were drawn from an ongoing clinical study at the University of
96 Virginia. This study has been approved by the Institutional Review Board and is
97 registered under ClinicalTrials.gov ID NCT02797288. Study subjects (aged 18-85) were
98 recruited from recurrent CDI patients scheduled for FMT therapy through colonoscopy
99 in the UVA outpatient clinic. Donor FMT material was obtained from a screened stool
100 bank (OpenBiome, Cambridge, MA). Follow-up collection of biopsies was also
101 performed approximately two months (mean = 63.2 days) from the date of FMT
102 administration.

103

104 **Biopsy Collection and Preservation**

105 Biopsy samples were collected from the distal colon during the FMT colonoscopy and
106 by sigmoid colonoscopy at scheduled follow-up. Biopsies were either immediately flash
107 frozen or stored in Allprotect tissue reagent (Qiagen) and then flash frozen. Frozen
108 biopsies were then stored at -80°C until analysis. Two biopsies were used at both pre-
109 and post-FMT timepoints for RNA isolation and subsequent sequencing. Due to a
110 change in collection protocol, two Allprotect biopsies were used for six patients, while
111 one AllProtect biopsy and one flash frozen biopsy were used for the other ten
112 patients. Additional biopsies were formalin-fixed and paraffin-embedded (FFPE) for
113 Hematoxylin and Eosin (H&E) staining and tissue visualization.

114

115 **Bulk RNA Sequencing and Bioinformatics**

116 Biopsies stored for RNA sequencing as described above were first transferred to clean
117 2ml screw-cap tubes containing a sterile 5mm stainless steel bead, then homogenized
118 using a TissueLyser II (Qiagen) for 3 minutes at 25Hz. Homogenized tissue was
119 vortexed and then RNA isolated using the RNeasy kit (Qiagen) according to the
120 manufacturer's protocol. RNA yield and quality was evaluated using a TapeStation
121 (Agilent), then stored at -80°C until use. Purified total RNA was submitted to Novogene
122 for bulk RNA sequencing. Libraries were generated after Poly(A) enrichment for mRNA
123 transcripts, followed by paired-end 150 base pair sequencing using a NovaSeq X Plus
124 series sequencer (Illumina).

125

126 Prior to analysis, unprocessed sequencing reads were evaluated for quality using
127 FastQC (31) and MultiQC (32), trimmed to remove adapter sequences using BBTools,
128 and pseudomapped to the human genome using Kallisto (33). The resulting count
129 tables were imported into R (34) using TxImport (35) and the DESeq2 package (36) was
130 used to exclude genes with low counts, normalize data, estimate dispersions, and fit
131 counts using a negative binomial model. Differential gene expression was determined
132 based on this multivariate model.

133

134 Gene Set Enrichment Analysis (GSEA) was performed using the fgsea package (37) in
135 R. Briefly, all genes included in the data set were ranked from most upregulated to most
136 downregulated post-FMT according to their Wald statistic from the multivariate model.
137 This ranked list was used for GSEA using the Hallmark (38), Gene Ontology (39), or

138 Kyoto Encyclopedia of Genes and Genomes (40) data sets. The tidyverse package (41)
139 was used for data organization and visualization.

140

141 **Histology and Crypt Length Measurement**

142 Slides containing FFPE biopsy sections were stained with H&E and imaged for crypt
143 length quantification. At least three crypts from two different regions were selected from
144 each slide. Crypt lengths were calculated using Sedeen slide viewer software
145 (Pathcore). Researchers were blinded to the FMT status of each slide at the time of
146 histopathologic analysis. After collection of all scores, means and standard deviations
147 were calculated on a per-slide and per-patient basis at both pre-FMT and post-FMT
148 timepoints. Statistics were performed on per-patient average pre- and post-FMT crypt
149 lengths using a linear mixed effects model that incorporated patient ID to control for
150 within-patient variability.

151

152 **Results and Discussion**

153 **Patient Characteristics**

154 A total of 16 patients with recurrent CDI undergoing FMT therapy provided colonic
155 biopsy samples at both FMT and follow-up appointments. The clinical characteristics of
156 this cohort are summarized in Table 1. Patients in the cohort were majority female and
157 entirely white. While 94% of patients had at least 3 recurrences prior to FMT (mean =
158 3.8), FMT therapy was successful in all patients as defined by no recurrences within the
159 follow-up window. All patients were treated with vancomycin prior to FMT treatment
160 (standard of care at UVA hospital), and no patients used antibiotics during the follow-up

161 period post-FMT. IBD was not a major confounder of this study, as only one patient had
162 an IBD diagnosis in this cohort.

163

164 **FMT Promotes Broad Changes in Intestine Transcriptional Profiles**

165 To evaluate the effect of FMT on host gene expression, bulk RNA sequencing
166 (RNAseq) was performed on biopsies collected immediately pre-FMT and at two month
167 follow-up. Reads from bulk RNAseq were processed to preserve only high quality reads
168 (>Q30, indicating 99.9% base calling accuracy) and remove adapter content. After this,
169 the clean reads were pseudomapped to the human genome using Kallisto, with 80% of
170 these reads successfully mapped and used for downstream analysis. Differentially
171 Expressed Genes (DEGs) were calculated using a negative binomial multivariate model
172 that incorporated patient ID number to account for within-patient variability. A total of
173 1,877 genes were significantly upregulated post-FMT (adjusted p value < 0.05), while
174 1,788 were downregulated (Fig. 1A). The 3,665 total DEGs represented approximately
175 15% of annotated genes included in the analysis. Of these differentially expressed
176 genes, 154 (8.2%) and 182 (10.2%) genes had at least a two-fold increase or decrease
177 in gene expression, respectively. Together, these results indicate that FMT promotes
178 large changes in gene expression that persist out to two month follow-up.

179

180 The 50 most differentially expressed genes between timepoints are presented in Figure
181 1B. Hierarchical clustering was performed with these data and samples clustered
182 primarily according to FMT status. The most prominent gene significantly increased
183 post-FMT was *FOSL1*, a FOS family protein that heterodimerizes to form the

184 transcription factor AP-1 (42). *FOSL1* is upregulated in cancer cells in a kRAS-
185 dependent manner (43) and is associated with increased stemness in cancer cells,
186 potentially through mutual regulation with NF-kB (44). Other significantly increased
187 genes included genes associated with extracellular matrix remodeling, such as *MMP1*
188 and *SERPINB5*. These genes have been implicated as markers of epithelial-
189 mesenchymal transition and poor prognosis in colorectal cancer samples (45).
190 Downregulated genes include genes such as *SLC6A19*, *KCNG1*, *ENPP1*, *NDRG1*, and
191 *PLOD2*. *SLC6A19* is a neutral amino acid transporter that is strongly repressed in stem
192 cells via *SOX9* (46), and loss of this gene is associated with protein restriction and
193 decreased mTORc1 activity (47). *ENPP1* is an extracellular cGAMP hydrolase, and its
194 activity is associated with degradation of immunomodulatory signaling and less efficient
195 inhibition of cancer growth and metastasis (48). Overall, these results point to a more
196 proliferative environment post-FMT.

197

198 These findings were broadly consistent with findings from our previous cohort: 51.6% of
199 differentially expressed genes in Jan *et al* were also significantly altered in this data set.
200 This includes several of the most differentially expressed genes from Figure 1B, such as
201 *MMP1*, *SERPINB5*, and *SLC6A19*.

202

203 **Pathway Analysis with RNAseq Data**

204 We aimed to take a more systematic approach to identifying biological pathways that
205 were altered by FMT. To do this, RNA sequencing data were analyzed using Gene Set
206 Enrichment Analysis (GSEA) to identify potential functions that were enriched pre- or

207 post-FMT. Three different databases were used for this analysis: Hallmark, Gene
208 Ontology: Biological Processes (GO:BP) and Kyoto Encyclopedia of Genes and
209 Genomes (KEGG). We took this approach to increase our coverage of biological
210 pathways, as each database contains slightly different gene sets and together they
211 provide a more comprehensive view of pathways whose expression may be modified by
212 FMT. The top five enriched gene sets for each database in both upregulated and
213 downregulated post-FMT conditions are presented in Figure 2, while all gene sets are
214 presented in Supplementary Table 1.

215

216 The most prominently upregulated process in post-FMT biopsy samples was ribosomal
217 biogenesis and protein processing (Fig. 2A). Ribosome and protein synthesis gene sets
218 were significantly enriched post-FMT in both GO:BP and KEGG databases, making up
219 most of the top 5 enriched gene sets. Analysis of leading edge genes (those driving
220 enrichment of each gene set in GSEA) found that GO:BP gene sets were primarily
221 driven by the same core set of genes. These genes were primarily regulators of
222 ribosome biogenesis and maturation (*RRP15*, *RRS1*, *BYSL*, *UTP11*, *MAK16*) or nuclear
223 proteins (*NUP88*, *NOP16*), many of which have been implicated in cell proliferation in
224 models of cancer (49–51). Ribosome biosynthesis, a process that starts in the nucleus
225 and continues in the cytoplasm, is a critical process required for the level of protein
226 production necessary for cell proliferation (52, 53). GSEA using KEGG gene sets also
227 identified Ribosomes as the most strongly enriched gene set along with other gene sets
228 associated with gene expression (Spliceosome, RNA Polymerase) and subsequent

229 protein processing (Protein Export, Proteasome). This highlights the high level of
230 metabolic activity post-FMT through the synthesis of new proteins.

231
232 Hallmark gene sets exhibited slightly different gene sets. The most enriched gene sets
233 from this database were downstream targets of several signal transduction molecules,
234 including Myc, mTORc1, and E2F. Myc and mTORc1 are major regulators of ribosomal
235 biogenesis and subsequent protein synthesis (54, 55), and many of the genes observed
236 in these gene sets are indicative of these processes. The Unfolded Protein Response
237 was also upregulated post-FMT, including genes such as *HYOU1*, *HSPA4*, and *BAG3*,
238 which are associated with response to misfolded protein stress that may result from
239 increased protein synthesis. Similarly, Proteasome genes were also enriched in the
240 KEGG database and are likely a response to increased protein synthesis and turnover.
241 Proteasome machinery is critical for proper cell proliferation, and proteasome inhibitors
242 are a clinically approved therapy for several cancers (56).

243
244 Several gene sets were downregulated post-FMT (Fig. 2B). The most prominent
245 downregulated signature was fatty acid catabolism, which was prominent in the Top 5
246 most enriched gene sets for both GO:BP and KEGG databases. This was driven by
247 enzymes in the fatty acid beta-oxidation pathway, including *ACOX1*, *ACAA2*, *ADH1C*,
248 and *ACSL5*. Bile acid metabolism was also significantly decreased post-FMT. These
249 changes in lipid metabolism, namely downregulation of fatty acid and bile acid
250 metabolism pathways, were also observed post-FMT in our previous study investigating
251 a mouse model of FMT treatment (57). The microbiota play a significant role in both lipid

252 metabolism (58) and insulin sensitivity (59), so these transcriptional changes may be
253 due to differences in host metabolism and energy production driven by differences in
254 microbial metabolism of the diet. Indeed, host energy metabolism pathways Glycolysis
255 and Oxidative Phosphorylation were both significantly enriched post-FMT
256 (Supplementary Table 1), suggesting that a shift from Glycolysis to fatty acid beta-
257 oxidation may occur in the absence of the microbiome. Bile acids also play a major role
258 in lipid absorption through fat emulsification and solubilization (60). The intestinal
259 microbiota are capable of modifying these bile acids and antibiotic treatment disrupts
260 this process, altering intestinal bile acid composition (61).

261

262 IFN α and IFN γ signaling were also decreased post-FMT, and these pathways were
263 primarily driven by a core set of interferon-stimulated (*IFIT1*, *IFIT2*, *GZMA*) and
264 apoptosis-associated (*CASP7*, *CASP3*) genes. Gene sets associated with Bile Acid
265 Metabolism, Fatty Acid Metabolism, and IFN α and IFN γ Responses were all enriched
266 in antibiotic-treated mice compared to naive controls (62), indicating that these
267 transcriptional changes are likely due to antibiotic-mediated disruption of the intestinal
268 microbiota. Finally, genes that were downregulated by kRAS signaling were also
269 downregulated post-FMT, which is consistent with the upregulation of *FOSL1*, a kRAS-
270 upregulated gene (43), observed in Figure 1B. kRAS is a small GTPase that plays a key
271 role in maintenance of intestinal homeostasis. It is activated by many extracellular
272 stimuli, including EGFR signaling, and is able to transduce those signals through
273 activation of downstream signaling pathways such as Raf/Erk and PI3K/Akt/mTOR to

274 promote cell proliferation or intestinal renewal (63). This served as additional evidence
275 that FMT promotes signaling pathways that promote cell proliferation.

276

277 **FMT is associated with Colonic Crypt Elongation that Correlates with Myc and**
278 **mTORc1 Target Gene Expression**

279 Because we observed enrichment of gene sets associated with increased metabolic
280 activity (Ribosome Biogenesis, Protein Export, Myc and mTORc1 Signaling), we
281 hypothesized that the epithelium would experience significant proliferation post-FMT. To
282 test this, we measured crypt length in H&E stained colonic biopsies, as crypt elongation
283 has been associated with elevation of cell proliferation markers such as Ki67 or LGR5
284 (64, 65). Crypt length was measured from multiple slides per patient at each timepoint in
285 a blinded fashion. Statistical differences were determined by comparing the average
286 crypt length pre- and post-FMT in a linear model controlling for within-patient variability.
287 Average crypt length was significantly longer in patients post-FMT (Fig. 3A-B),
288 suggesting that FMT stimulated epithelial cell proliferation. Of note, CDI was previously
289 associated in a mouse study with elongated crypt length, with FMT paradoxically
290 restoring colonic crypts to a shorter length more similar to uninfected mice (66). This
291 finding was in the context of acute infection with *C. difficile* and the resulting
292 inflammatory immune response, which was already promoting increased crypt length.
293 This is consistent with other infections where crypt elongation has been observed, such
294 as *Salmonella* Typhimurium (67) and HIV (68). Broad inflammatory signaling was
295 largely absent from our RNA sequencing data, consistent with our earlier finding that
296 FMT promotes Type 2 immunity in humans (30). We hypothesize that this anti-

297 inflammatory colonic environment likely contributes to the differential effects of FMT on
298 crypt length.

299

300 One of the strongest signatures from the RNAseq data was Myc target genes. Because
301 these signaling pathways are known to promote ribosome biogenesis, protein
302 production, and cell proliferation, we hypothesized that crypt length would correlate with
303 the expression of target genes in these pathways. To test this, expression of the top 10
304 leading edge genes for both Myc and mTORc1 Target Genes were tested for correlation
305 with crypt length from both pre- and post-FMT samples. Overall, 6/10 Myc Target genes
306 and 4/10 mTORc1 Target leading edge genes were significantly correlated with crypt
307 length, and all trended towards a positive correlation (Fig. 4A), indicating that these
308 pathways are associated with increased crypt cell proliferation. Previous work has
309 shown the Myc is required for proliferation of crypt progenitor cells, as crypts in which
310 Myc has been knocked out are quickly lost and replaced by Myc-sufficient crypts (69).
311 These Myc-deficient crypts were associated with fewer cell numbers per crypt, smaller
312 cell sizes, and reduced biosynthetic activity compared to Myc-sufficient crypts. The most
313 differentially expressed Myc target gene in our data set was *ODC1*, the rate limiting
314 enzyme for polyamine biosynthesis. *SRM*, another polyamine biosynthesis gene, was
315 also a Myc Target gene, further implicating this pathway. Polyamine biosynthesis
316 genes, including *ODC1*, have been implicated in ribosome homeostasis, as depletion of
317 these genes was associated with impaired biogenesis (70). Polyamines are also
318 important sources of energy for enterocytes, making them critical for epithelial renewal
319 and proper barrier function in the gut (71), which supports their potential role in cell

320 proliferation. Both *ODC1* and *SRM* expression were significantly correlated with colonic
321 crypt length (Fig. 4B-C), suggesting that polyamine biosynthesis and utilization may be
322 one potential mechanism by which crypt elongation occurs. Overall, these results
323 provide additional evidence that FMT treatment promotes cell proliferation in the
324 intestinal epithelium.

325

326 **IL-33 and EGFR Signaling Ligands Are Upregulated Post-FMT**

327 Based on the enrichment in Myc and mTORc1 target genes post-FMT and their
328 association with increased protein production and changes in crypt length, we were
329 interested in determining potential upstream mechanisms of action. mTORc1 and E2F
330 signaling cascades can both be stimulated by EGFR signaling through PI3K/Akt and
331 Ras/Raf/Erk signaling cascades, respectively (72). In addition, Ras/Raf/Erk and
332 PI3K/Akt signaling can significantly increase the half-life of Myc protein and thus
333 enhance its effects on transcription (73). Based on these data, we hypothesized that
334 EGFR signaling may be partially responsible the significant increase in Myc, mTORc1,
335 and E2F target genes observed in our GSEA. We observed that several ligands of
336 EGFR were significantly upregulated post-FMT, including amphiregulin (*AREG*),
337 epiregulin (*EREG*) and heparin-binding EGF-like growth factor (*HB-EGF*) (Fig. 5A).

338

339 Previous studies in our group have identified Type 2 immune responses in both animal
340 models of FMT and human patients (23, 30). Innate Lymphoid Cell 2s (ILC2s), which
341 are critical for the intestinal Type 2 immune response, are responsive to signals from
342 the microbiome (74). Our group has recently observed that antibiotic treatment

343 significantly decreased ILC2 populations, while IL-33 treatment restored these
344 populations (75). ILC2s robustly produced AREG in response to IL-33 treatment, and
345 this was protective against acute CDI. Based on these data, we hypothesized that Type
346 2 immunity, particularly IL-33 signaling, may be upregulated post-FMT. We observed
347 that IL-33 signaling was differentially expressed, with transcripts of both the cytokine
348 (*IL33*) and receptor (*IL1RL1/ST2*) significantly increased post-FMT (Fig. 5B). ILC2-
349 derived AREG can signal through EGFR to promote intestinal tissue repair, and
350 disruption of this signaling is associated with inflammatory bowel disease in both animal
351 and human models (76). In addition, HB-EGF signaling through EGFR can feed back on
352 this process to increase IL-33 expression, and this upregulation is required for wound
353 repair in HB-EGF treated keratinocytes (77). IL-33/ST2 Signaling and resulting
354 production of AREG and other EGFR ligands may therefore promote cell proliferation
355 and intestinal repair observed post-FMT.

356

357 IL-33 signaling has been shown to promote expression of several matrix
358 metalloproteinases (MMPs) (78), which may be one mechanism by which FMT
359 promotes tissue remodeling and restoration of homeostasis. We identified extracellular
360 matrix remodeling genes (*MMP1*, *SERPINB5*) as some of the most highly upregulated
361 genes post-FMT (Fig. 1B). Consistent with this, we also found that the gene set for
362 epithelial-mesenchymal transition (EMT), which is associated with tissue repair and
363 regeneration, was significantly enriched post-FMT by GSEA (Supplementary Table 1).
364 EMT is characterized by the transition of polarized epithelial cells to mesenchymal cells
365 with increased cell mobility and increased production of extracellular matrix proteins. As

366 part of this process, these cells also upregulate MMPs, which can remodel the
367 extracellular matrix, along with MMP inhibitors such as tissue inhibitors of
368 metalloproteases (TIMPs) or serine protease inhibitors (SERPINs) (79). Further
369 targeted analysis of differentially expressed genes identified several MMPs that were
370 significantly increased post-FMT (Fig. 5C) as well as inhibitors of this process (*TIMP1*,
371 *SERPINB5*). MMP regulation can be induced by several signaling cascades, including
372 NF- κ B and MAPK pathways as well as AP-1 binding to MMP promoter regions (80), all
373 pathways that have been implicated in our data. Furthermore, knockdown of MMP1
374 using shRNA resulted in decreased EMT and decreased Akt and Myc expression in a
375 colorectal cancer cell line (81), suggesting that expression of these genes may sustain
376 activation of these pathways. Overall, these results are consistent with an environment
377 associated with intestinal regeneration and repair.

378

379 **Conclusions**

380 A potential model of how the pathways implicated by our transcriptional data may
381 contribute to changes in crypt length and intestinal repair is presented in Figure 6. We
382 observed that post-FMT colonic biopsies exhibit longer crypt length than those pre-FMT,
383 suggesting that FMT promotes cell proliferation. Utilizing bulk RNA sequencing of these
384 biopsy samples, we observed distinct expression profiles between conditions with many
385 differentially expressed genes, particularly in pathways associated with protein
386 synthesis and processing as well as extracellular matrix reorganization. Target genes in
387 the Myc and mTORc1 pathways were significantly correlated with crypt length in these
388 patients, including genes associated with polyamine biosynthesis, an important pathway

389 for energy production in enterocytes. We also observed significant changes in IL-33
390 signaling and EGFR ligand genes, suggesting that IL-33 signaling and resulting
391 production of EGFR ligands may underlie these changes.

392

393 Further research is necessary to confirm the mechanistic links between these pathways
394 and the changes in cell proliferation and crypt length observed in our histological data.
395 However, these data suggest that FMT promotes regeneration of the intestine within a
396 cohort of patients with recurrent CDI, and that this is associated with broad
397 transcriptional changes in pathways such as Myc, mTOR, IL-33, and EGFR signaling.

398

399 **Acknowledgements**

400 We would like to thank the subjects in the FMT clinical trial for their cooperation and
401 participation in this study. This work was supported by NIH grants R01 AI152477 and
402 R01 AI124214 and the Henske Family. We are indebted to Drs. Jashim Uddin, Farha
403 Naz, Mayuresh Abhyankar and Chelsea Marie for excellent discussion and review of
404 this manuscript.

405

406 **Conflicts of Interest**

407 WAP is a consultant for TechLab, Inc. that produces diagnostics for *C. difficile*. The
408 other authors report no conflicts of interest.

409

410 **Figure 1: FMT drives changes in host transcriptional profiles.** Colonic biopsy
411 samples were collected immediately pre-FMT or at two month follow-up post-FMT and

412 used to evaluate host transcriptional profiles using bulk RNA sequencing. A) Volcano
413 plot showing differentially expressed genes (DEGs) that are increased (blue) or
414 decreased (red) in patients post-FMT compared to baseline. B) Heatmap of 50 most
415 differentially expressed genes between pre- and post-FMT biopsy samples.

416

417 **Figure 2: Gene sets associated with ribosome/protein synthesis and lipid**
418 **metabolism are altered by FMT.** Ranked barplot of the most significantly increased (A)
419 or decreased (B) gene sets post-FMT as determined by Gene Set Enrichment Analysis
420 (GSEA). Top five gene sets are shown for the Hallmark (red), Gene Ontology: Biological
421 Processes (green) and KEGG (blue) databases. Genes are ranked according to
422 Normalized Enrichment Score.

423

424 **Figure 3: FMT promotes increased colonic crypt length.** A) Representative H&E
425 images of crypts from colonic biopsies from the same patient pre- and post-FMT. B)
426 Quantification of average crypt length across all patients. Each dot represents a single
427 patient and gray lines connect paired samples. Statistics were calculated using a linear
428 mixed effects model controlling for within-patient variability. ***, $p < 0.001$

429

430 **Figure 4: Crypt length is correlated with Myc and mTORc1 target genes.** A)
431 Heatmap showing the Pearson correlation R value for the top 10 leading edge genes
432 driving enrichment of Myc and mTORc1 Target gene sets in GSEA. Significantly
433 correlated genes are indicated with asterisks. B-C) Correlation plots showing correlation

434 between average crypt length and normalized gene counts for *ODC1* (B) or *SRM* (C),
435 rate limiting genes for polyamine biosynthesis. *, $p < 0.05$; **, $p < 0.01$

436

437 **Figure 5: FMT promotes expression of IL-33 signaling, EGFR ligand, and tissue**

438 **remodeling genes.** Normalized gene counts of select A) EGFR ligand, B) IL-33

439 signaling, and C) tissue remodeling genes either pre-FMT (red) or post-FMT (blue).

440 Statistics are derived from the DESeq2 multivariate model, which adjusts for multiple

441 comparisons. *, $p < 0.05$; **, $p < 0.01$, ***, $p < 0.001$; ****, $p < 0.0001$

442

443 **Figure 6: Visual summary of FMT-promoted changes in colonic gene expression.**

444 FMT is associated with significant increases in IL-33 signaling genes. IL-33 signaling

445 promotes expression of EGFR ligands, including amphiregulin, which can stimulate

446 Erk/MAPK and PI3K/Akt/mTOR signaling cascades. Erk and mTOR also stabilize Myc

447 protein levels, promoting enhanced expression of Myc-activated genes. Myc and

448 mTORc1 target genes promote ribosome biogenesis, protein synthesis and processing,

449 and biosynthesis of polyamines, which promote proliferation of intestinal epithelial cells.

450 Meanwhile, Erk signaling activates c-Fos, a component of the AP-1 transcription factor

451 that increases matrix metalloprotease expression and promotes remodeling and repair

452 of the extracellular matrix.

453

454 **References**

- 455 1. Finn E, Andersson FL, Madin-Warburton M. 2021. Burden of *Clostridioides*
456 *difficile* infection (CDI) - a systematic review of the epidemiology of primary and

- 457 recurrent CDI. BMC Infect Dis 21:456.
- 458 2. Feuerstadt P, Nelson WW, Drozd EM, Dreyfus J, Dahdal DN, Wong AC,
459 Mohammadi I, Teigland C, Amin A. 2022. Mortality, Health Care Use, and Costs
460 of Clostridioides difficile Infections in Older Adults. J Am Med Dir Assoc 23:1721-
461 1728.e19.
- 462 3. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE,
463 Dubberke ER, Garey KW, Gould C V, Kelly C, Loo V, Shaklee Sammons J,
464 Sandora TJ, Wilcox MH. 2018. Clinical Practice Guidelines for Clostridium difficile
465 Infection in Adults and Children: 2017 Update by the Infectious Diseases Society
466 of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).
467 Clin Infect Dis 66:e1–e48.
- 468 4. Singh T, Bedi P, Bumrah K, Singh J, Rai M, Seelam S. 2019. Updates in
469 Treatment of Recurrent Clostridium difficile Infection. J Clin Med Res Vol 11, No
470 7, Jul 2019.
- 471 5. Madden GR, Boone RH, Lee E, Sifri CD, Petri Jr. WA. 2024. Predicting
472 Clostridioides difficile infection outcomes with explainable machine
473 learning. eBioMedicine 106.
- 474 6. Feuerstadt P, Louie TJ, Lashner B, Wang EEL, Diao L, Bryant JA, Sims M, Kraft
475 CS, Cohen SH, Berenson CS. 2022. SER-109, an oral microbiome therapy for
476 recurrent Clostridioides difficile infection. N Engl J Med 386:220–229.
- 477 7. Dubberke ER, Orenstein R, Khanna S, Guthmueller B, Lee C. 2023. Final results
478 from a phase 2b randomized, placebo-controlled clinical trial of RBX2660: a
479 microbiota-based drug for the prevention of recurrent Clostridioides difficile

- 480 infection. *Infect Dis Ther* 12:703–709.
- 481 8. Slimings C, Riley T V. 2014. Antibiotics and hospital-acquired *Clostridium difficile*
482 infection: update of systematic review and meta-analysis. *J Antimicrob*
483 *Chemother* 69:881–891.
- 484 9. Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DDK, Sferra TJ,
485 Hernandez A V, Donskey CJ. 2013. Community-associated *Clostridium difficile*
486 infection and antibiotics: a meta-analysis. *J Antimicrob Chemother* 68:1951–
487 1961.
- 488 10. Gotoh K, Sakaguchi Y, Kato H, Osaki H, Jodai Y, Wakuda M, Také A, Hayashi S,
489 Morita E, Sugie T, Ito Y, Ohmiya N. 2022. Fecal microbiota transplantation as
490 therapy for recurrent *Clostridioides difficile* infection is associated with
491 amelioration of delirium and accompanied by changes in fecal microbiota and the
492 metabolome. *Anaerobe* 73:102502.
- 493 11. Weingarden AR, Chen C, Bobr A, Yao D, Lu Y, Nelson VM, Sadowsky MJ,
494 Khoruts A. 2014. Microbiota transplantation restores normal fecal bile acid
495 composition in recurrent *Clostridium difficile* infection. *Am J Physiol Gastrointest*
496 *Liver Physiol* 2013/11/27. 306:G310–G319.
- 497 12. Brown JR-M, Flemer B, Joyce SA, Zulquernain A, Sheehan D, Shanahan F,
498 O'Toole PW. 2018. Changes in microbiota composition, bile and fatty acid
499 metabolism, in successful faecal microbiota transplantation for *Clostridioides*
500 *difficile* infection. *BMC Gastroenterol* 18:131.
- 501 13. Foley MH, Walker ME, Stewart AK, O'Flaherty S, Gentry EC, Patel S, Beaty V V,
502 Allen G, Pan M, Simpson JB, Perkins C, Vanhoy ME, Dougherty MK, McGill SK,

- 503 Gulati AS, Dorrestein PC, Baker ES, Redinbo MR, Barrangou R, Theriot CM.
504 2023. Bile salt hydrolases shape the bile acid landscape and restrict
505 *Clostridioides difficile* growth in the murine gut. *Nat Microbiol* 8:611–628.
- 506 14. L. JM, L. LJ, B. YV, D. SP. 2017. *Clostridium difficile* Colonizes Alternative
507 Nutrient Niches during Infection across Distinct Murine Gut Microbiomes.
508 *mSystems* 2:10.1128/msystems.00063-17.
- 509 15. Zheng D, Liwinski T, Elinav E. 2020. Interaction between microbiota and immunity
510 in health and disease. *Cell Res* 30:492–506.
- 511 16. Steiner TS, Flores CA, Pizarro TT, Guerrant RL. 1997. Fecal lactoferrin,
512 interleukin-1beta, and interleukin-8 are elevated in patients with severe
513 *Clostridium difficile* colitis. *Clin Diagn Lab Immunol* 4:719–722.
- 514 17. Jiang Z-D, DuPont HL, Garey K, Price M, Graham G, Okhuysen P, Dao-Tran T,
515 LaRocco M. 2006. A common polymorphism in the interleukin 8 gene promoter is
516 associated with *Clostridium difficile* diarrhea. *Am J Gastroenterol* 101:1112–
517 1116.
- 518 18. El Feghaly RE, Stauber JL, Deych E, Gonzalez C, Tarr PI, Haslam DB. 2013.
519 Markers of intestinal inflammation, not bacterial burden, correlate with clinical
520 outcomes in *Clostridium difficile* infection. *Clin Infect Dis* 2013/03/13. 56:1713–
521 1721.
- 522 19. Saleh MM, Frisbee AL, Leslie JL, Buonomo EL, Cowardin CA, Ma JZ, Simpson
523 ME, Scully KW, Abhyankar MM, Petri WA. 2019. Colitis-Induced Th17 Cells
524 Increase the Risk for Severe Subsequent *Clostridium difficile* Infection. *Cell Host*
525 *Microbe* 25:756-765.e5.

- 526 20. Buonomo EL, Cowardin CA, Wilson MG, Saleh MM, Pramoonjago P, Petri WAJ.
527 2016. Microbiota-Regulated IL-25 Increases Eosinophil Number to Provide
528 Protection during *Clostridium difficile* Infection. *Cell Rep* 16:432–443.
- 529 21. Cowardin CA, Buonomo EL, Saleh MM, Wilson MG, Burgess SL, Kuehne SA,
530 Schwan C, Eichhoff AM, Koch-Nolte F, Lyras D. 2016. The binary toxin CDT
531 enhances *Clostridium difficile* virulence by suppressing protective colonic
532 eosinophilia. *Nat Microbiol* 1:1–10.
- 533 22. Frisbee AL, Saleh MM, Young MK, Leslie JL, Simpson ME, Abhyankar MM,
534 Cowardin CA, Ma JZ, Pramoonjago P, Turner SD, Liou AP, Buonomo EL, Petri
535 WA. 2019. IL-33 drives group 2 innate lymphoid cell-mediated protection during
536 *Clostridium difficile* infection. *Nat Commun* 10:2712.
- 537 23. Moreau GB, Naz F, Petri WAJ. 2024. Fecal microbiota transplantation stimulates
538 type 2 and tolerogenic immune responses in a mouse model. *Anaerobe*
539 86:102841.
- 540 24. Wang Z, Hua W, Li C, Chang H, Liu R, Ni Y, Sun H, Li Y, Wang X, Hou M, Liu Y,
541 Xu Z, Ji M. 2019. Protective Role of Fecal Microbiota Transplantation on Colitis
542 and Colitis-Associated Colon Cancer in Mice Is Associated With Treg Cells. *Front*
543 *Microbiol* 10:2498.
- 544 25. Burrello C, Garavaglia F, Cribiù FM, Ercoli G, Lopez G, Troisi J, Colucci A,
545 Guglietta S, Carloni S, Guglielmetti S, Taverniti V, Nizzoli G, Bosari S, Caprioli F,
546 Rescigno M, Facciotti F. 2018. Therapeutic faecal microbiota transplantation
547 controls intestinal inflammation through IL10 secretion by immune cells. *Nat*
548 *Commun* 9:5184.

- 549 26. Wei Y-L, Chen Y-Q, Gong H, Li N, Wu K-Q, Hu W, Wang B, Liu K-J, Wen L-Z,
550 Xiao X, Chen D-F. 2018. Fecal Microbiota Transplantation Ameliorates
551 Experimentally Induced Colitis in Mice by Upregulating AhR. *Front Microbiol*
552 9:1921.
- 553 27. Konturek PC, Koziel J, Dieterich W, Haziri D, Wirtz S, Glowczyk I, Konturek K,
554 Neurath MF, Zopf Y. 2016. Successful therapy of *Clostridium difficile* infection
555 with fecal microbiota transplantation. *J Physiol Pharmacol an Off J Polish*
556 *Physiol Soc* 67:859–866.
- 557 28. Monaghan T, Mullish BH, Patterson J, Wong GKS, Marchesi JR, Xu H, Jilani T,
558 Kao D. 2019. Effective fecal microbiota transplantation for recurrent *Clostridioides*
559 *difficile* infection in humans is associated with increased signalling in the bile acid-
560 farnesoid X receptor-fibroblast growth factor pathway. *Gut Microbes* 10:142–148.
- 561 29. Monaghan TM, Seekatz AM, Markham NO, Yau TO, Hatzia Apostolou M, Jilani T,
562 Christodoulou N, Roach B, Birli E, Pomenya O, Louie T, Lacy DB, Kim P, Lee C,
563 Kao D, Polytarchou C. 2021. Fecal Microbiota Transplantation for Recurrent
564 *Clostridioides difficile* Infection Associates With Functional Alterations in
565 Circulating microRNAs. *Gastroenterology* 161:255-270.e4.
- 566 30. Jan N, Hays RA, Oakland DN, Kumar P, Ramakrishnan G, Behm BW, Petri WA,
567 Marie C. 2021. Fecal Microbiota Transplantation Increases Colonic IL-25 and
568 Dampens Tissue Inflammation in Patients with Recurrent *Clostridioides difficile*.
569 *mSphere* 6:10.1128/msphere.00669-21.
- 570 31. Andrews S. 2010. FastQC: a quality control tool for high throughput sequence
571 data. Babraham Bioinformatics, Babraham Institute, Cambridge, United Kingdom.

- 572 32. Ewels P, Magnusson M, Lundin S, Källér M. 2016. MultiQC: summarize analysis
573 results for multiple tools and samples in a single report. *Bioinformatics* 32:3047–
574 3048.
- 575 33. Bray NL, Pimentel H, Melsted P, Pachter L. 2016. Near-optimal probabilistic RNA-
576 seq quantification. *Nat Biotechnol* 34:525–527.
- 577 34. R Core Team. 2020. R: A language and environment for statistical computing.
- 578 35. Sonesson C, Love MI, Robinson MD. 2015. Differential analyses for RNA-seq:
579 transcript-level estimates improve gene-level inferences. *F1000Research* 4.
- 580 36. Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and
581 dispersion for RNA-seq data with DESeq2. *Genome Biol* 15:550.
- 582 37. Korotkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Sergushichev A.
583 2021. Fast gene set enrichment analysis. *bioRxiv* 060012.
- 584 38. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. 2015.
585 The Molecular Signatures Database Hallmark Gene Set Collection. *Cell Syst*
586 1:417–425.
- 587 39. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP,
588 Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A,
589 Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. 2000.
590 Gene Ontology: tool for the unification of biology. *Nat Genet* 25:25–29.
- 591 40. Kanehisa M, Goto S. 2000. KEGG: kyoto encyclopedia of genes and genomes.
592 *Nucleic Acids Res* 28:27–30.
- 593 41. Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, Golemund
594 G, Hayes A, Henry L, Hester J. 2019. Welcome to the Tidyverse. *J open source*

595 Softw 4:1686.

596 42. Song D, Lian Y, Zhang L. 2023. The potential of activator protein 1 (AP-1) in
597 cancer targeted therapy. *Front Immunol* 14.

598 43. Vallejo A, Perurena N, Guruceaga E, Mazur PK, Martinez-Canarias S, Zandueta
599 C, Valencia K, Arricibita A, Gwinn D, Sayles LC, Chuang C-H, Guembe L, Bailey
600 P, Chang DK, Biankin A, Ponz-Sarvise M, Andersen JB, Khatri P, Bozec A,
601 Sweet-Cordero EA, Sage J, Lecanda F, Vicent S. 2017. An integrative approach
602 unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic
603 cancer. *Nat Commun* 8:14294.

604 44. Ramar V, Guo S, Hudson B, Khedri A, Guo AA, Li J, Liu M. 2024. Interaction of
605 NF- κ B and FOSL1 drives glioma stemness. *Cell Mol Life Sci* 81:255.

606 45. Li H, Zhong A, Li S, Meng X, Wang X, Xu F, Lai M. 2017. The integrated pathway
607 of TGF β /Snail with TNF α /NF κ B may facilitate the tumor-stroma interaction in the
608 EMT process and colorectal cancer prognosis. *Sci Rep* 7:4915.

609 46. Tümer E, Bröer A, Balkrishna S, Jülich T, Bröer S. 2013. Enterocyte-specific
610 Regulation of the Apical Nutrient Transporter SLC6A19 (B⁰AT1) by Transcriptional
611 and Epigenetic Networks * . *J Biol Chem* 288:33813–33823.

612 47. Javed K, Bröer S. 2019. Mice Lacking the Intestinal and Renal Neutral Amino
613 Acid Transporter SLC6A19 Demonstrate the Relationship between Dietary
614 Protein Intake and Amino Acid Malabsorption. *Nutrients*.

615 48. Mardjuki R, Wang S, Carozza J, Zirak B, Subramanyam V, Abhiraman G, Lyu X,
616 Goodarzi H, Li L. 2024. Identification of the extracellular membrane protein
617 ENPP3 as a major cGAMP hydrolase and innate immune checkpoint. *Cell Rep*

- 618 43.
- 619 49. Dong Z, Zhu C, Zhan Q, Jiang W. 2017. The roles of RRP15 in nucleolar
620 formation, ribosome biogenesis and checkpoint control in human cells.
621 *Oncotarget* 8:13240–13252.
- 622 50. Gan Y, Deng J, Hao Q, Huang Y, Han T, Xu J-G, Zhao M, Yao L, Xu Y, Xiong J,
623 Lu H, Wang C, Chen J, Zhou X. 2023. UTP11 deficiency suppresses cancer
624 development via nucleolar stress and ferroptosis. *Redox Biol* 62:102705.
- 625 51. Sha Z, Zhou J, Wu Y, Zhang T, Li C, Meng Q, Musunuru PP, You F, Wu Y, Yu R,
626 Gao S. 2020. BYSL Promotes Glioblastoma Cell Migration, Invasion, and
627 Mesenchymal Transition Through the GSK-3 β / β -Catenin Signaling Pathway.
628 *Front Oncol* 10.
- 629 52. Gabut M, Bourdelais F, Durand S. 2020. Ribosome and Translational Control in
630 Stem Cells. *Cells*.
- 631 53. Elhamamsy AR, Metge BJ, Alsheikh HA, Shevde LA, Samant RS. 2022.
632 Ribosome Biogenesis: A Central Player in Cancer Metastasis and Therapeutic
633 Resistance. *Cancer Res* 82:2344–2353.
- 634 54. Destefanis F, Manara V, Bellosta P. 2020. Myc as a Regulator of Ribosome
635 Biogenesis and Cell Competition: A Link to Cancer. *Int J Mol Sci*.
- 636 55. Jiao L, Liu Y, Yu X-Y, Pan X, Zhang Y, Tu J, Song Y-H, Li Y. 2023. Ribosome
637 biogenesis in disease: new players and therapeutic targets. *Signal Transduct*
638 *Target Ther* 8:15.
- 639 56. Narayanan S, Cai C-Y, Assaraf YG, Guo H-Q, Cui Q, Wei L, Huang J-J, Ashby
640 CR, Chen Z-S. 2020. Targeting the ubiquitin-proteasome pathway to overcome

- 641 anti-cancer drug resistance. *Drug Resist Updat* 48:100663.
- 642 57. Moreau B. 2013. Characterization of Francisella-Scavenger Receptor Interactions
643 and Contributions to Host Signaling Qualifying Exam.
- 644 58. Schoeler M, Caesar R. 2019. Dietary lipids, gut microbiota and lipid metabolism.
645 *Rev Endocr Metab Disord* 20:461–472.
- 646 59. Canfora EE, Jocken JW, Blaak EE. 2015. Short-chain fatty acids in control of
647 body weight and insulin sensitivity. *Nat Rev Endocrinol* 11:577–591.
- 648 60. Begley M, Gahan CGM, Hill C. 2005. The interaction between bacteria and bile.
649 *FEMS Microbiol Rev* 29:625–651.
- 650 61. Vrieze A, Out C, Fuentes S, Jonker L, Reuling I, Kootte RS, van Nood E,
651 Holleman F, Knaapen M, Romijn JA, Soeters MR, Blaak EE, Dallinga-Thie GM,
652 Reijnders D, Ackermans MT, Serlie MJ, Knop FK, Holst JJ, van der Ley C, Kema
653 IP, Zoetendal EG, de Vos WM, Hoekstra JBL, Stroes ES, Groen AK, Nieuwdorp
654 M. 2014. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and
655 insulin sensitivity. *J Hepatol* 60:824–831.
- 656 62. Suez J, Zmora N, Zilberman-Schapira G, Mor U, Dori-Bachash M, Bashiardes S,
657 Zur M, Regev-Lehavi D, Ben-Zeev Brik R, Federici S, Horn M, Cohen Y, Moor AE,
658 Zeevi D, Korem T, Kotler E, Harmelin A, Itzkovitz S, Maharshak N, Shibolet O,
659 Pevsner-Fischer M, Shapiro H, Sharon I, Halpern Z, Segal E, Elinav E. 2018.
660 Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics
661 and Improved by Autologous FMT. *Cell* 174:1406-1423.e16.
- 662 63. Ternet C, Kiel C. 2021. Signaling pathways in intestinal homeostasis and
663 colorectal cancer: KRAS at centre stage. *Cell Commun Signal* 19:31.

- 664 64. Jeffery V, Goldson AJ, Dainty JR, Chieppa M, Sobolewski A. 2017. IL-6 Signaling
665 Regulates Small Intestinal Crypt Homeostasis. *J Immunol* 199:304–311.
- 666 65. Li C, Zhou Y, Rychahou P, Weiss HL, Lee EY, Perry CL, Barrett TA, Wang Q,
667 Evers BM. 2020. SIRT2 Contributes to the Regulation of Intestinal Cell
668 Proliferation and Differentiation. *Cell Mol Gastroenterol Hepatol* 10:43–57.
- 669 66. Littmann ER, Lee J-J, Denny JE, Alam Z, Maslanka JR, Zarin I, Matsuda R,
670 Carter RA, Susac B, Saffern MS, Fett B, Mattei LM, Bittinger K, Abt MC. 2021.
671 Host immunity modulates the efficacy of microbiota transplantation for treatment
672 of *Clostridioides difficile* infection. *Nat Commun* 12:755.
- 673 67. Yan J, Racaud-Sultan C, Pezier T, Edir A, Rolland C, Claverie C, Burlaud-Gaillard
674 J, Olivier M, Velge P, Lacroix-Lamandé S, Vergnolle N, Wiedemann A. 2024.
675 Intestinal organoids to model *Salmonella* infection and its impact on progenitors.
676 *Sci Rep* 14:15160.
- 677 68. Batman PA, Kapembwa MS, Belmonte L, Tudor G, Kotler DP, Potten CS, Booth
678 C, Cahn P, Griffin GE. 2014. HIV enteropathy: HAART reduces HIV-induced stem
679 cell hyperproliferation and crypt hypertrophy to normal in jejunal mucosa. *J Clin*
680 *Pathol* 67:14–18.
- 681 69. Muncan V, Sansom OJ, Tertoolen L, Phesse TJ, Begthel H, Sancho E, Cole AM,
682 Gregorieff A, de Alboran IM, Clevers H, Clarke AR. 2006. Rapid Loss of Intestinal
683 Crypts upon Conditional Deletion of the Wnt/Tcf-4 Target Gene *c-Myc*. *Mol Cell*
684 *Biol* 26:8418–8426.
- 685 70. Dörner K, Badertscher L, Horváth B, Hollandi R, Molnár C, Fuhrer T, Meier R,
686 Sárázová M, van den Heuvel J, Zamboni N, Horvath P, Kutay U. 2022. Genome-

687 wide RNAi screen identifies novel players in human 60S subunit biogenesis
688 including key enzymes of polyamine metabolism. *Nucleic Acids Res* 50:2872–
689 2888.

690 71. Rao JN, Xiao L, Wang J-Y. 2020. Polyamines in Gut Epithelial Renewal and
691 Barrier Function. *Physiology (Bethesda)* 35:328–337.

692 72. Stefani C, Miricescu D, Stanescu-Spinu I-I, Nica RI, Greabu M, Totan AR, Jinga
693 M. 2021. Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in
694 Colorectal Cancer Pathogenesis: Where Are We Now? *Int J Mol Sci*.

695 73. Ahmadi SE, Rahimi S, Zarandi B, Chegeni R, Safa M. 2021. MYC: a multipurpose
696 oncogene with prognostic and therapeutic implications in blood malignancies. *J*
697 *Hematol Oncol* 14:121.

698 74. Ganai-Vonarburg SC, Duerr CU. 2020. The interaction of intestinal microbiota and
699 innate lymphoid cells in health and disease throughout life. *Immunology* 159:39–
700 51.

701 75. Jashim UM, Brandon T, L. LJ, Casey F, Katia S, Pankaj K, A. PW. 2024.
702 Investigating the impact of antibiotic-induced dysbiosis on protection from
703 *Clostridium difficile* colitis by mouse colonic innate lymphoid cells. *MBio*
704 15:e03338-23.

705 76. Hodzic Z, Schill EM, Bolock AM, Good M. 2017. IL-33 and the intestine: The
706 good, the bad, and the inflammatory. *Cytokine* 100:1–10.

707 77. Dai X, Shiraishi K, Muto J, Mori H, Murakami M, Sayama K. 2023. Nuclear IL-33
708 Plays an Important Role in EGFR-Mediated Keratinocyte Migration by Regulating
709 the Activation of Signal Transducer and Activator of Transcription 3 and NF-κB.

- 710 JID Innov 3:100205.
- 711 78. Andersson P, Yang Y, Hosaka K, Zhang Y, Fischer C, Braun H, Liu S, Yu G, Liu
712 S, Beyaert R, Chang M, Li Q, Cao Y. 2018. Molecular mechanisms of IL-33-
713 mediated stromal interactions in cancer metastasis. JCI insight 3.
- 714 79. Marconi GD, Fonticoli L, Rajan TS, Pierdomenico SD, Trubiani O, Pizzicannella J,
715 Diomede F. 2021. Epithelial-Mesenchymal Transition (EMT): The Type-2 EMT in
716 Wound Healing, Tissue Regeneration and Organ Fibrosis. Cells.
- 717 80. Fanjul-Fernández M, Folgueras AR, Cabrera S, López-Otín C. 2010. Matrix
718 metalloproteinases: Evolution, gene regulation and functional analysis in mouse
719 models. Biochim Biophys Acta - Mol Cell Res 1803:3–19.
- 720 81. Wang K, Zheng J, Yu J, Wu Y, Guo J, Xu Z, Sun X. 2020. Knockdown of MMP-1
721 inhibits the progression of colorectal cancer by suppressing the PI3K/Akt/c-myc
722 signaling pathway and EMT. Oncol Rep 43:1103–1112.
- 723
- 724

Table 1: Clinical Characteristics of the FMT Cohort

Clinical Characteristic		FMT Cohort (n=16)*
Mean age at FMT		65 (12.1)
Number male gender		6 (37.5%)
Number white ethnicity		16 (100%)
Mean BMI at FMT		29.9 (6.1)
Mean number of CDI recurrences prior to FMT		3.8 (1.1)
Number of patients with:	2 recurrences	1 (6.25%)
	3 recurrences	6 (37.5%)
	4 recurrences	6 (37.5%)
	5 recurrences	1 (6.25%)
	6 recurrences	2 (12.5%)
Number patients treated with vancomycin prior to FMT		16 (100%)
Number of patients with IBD		1 (6.25%)
Number of patients with IBD Subtypes	<i>Crohn's Disease</i>	1 (6.25%)
	<i>Ulcerative Colitis</i>	0 (0.0%)
FMT Success Rate (No recurrences within 60 day follow-up)		16 (100%)
Number of patients with current or prior antibiotic use at follow-up.		0 (0.0%)

*Represents Mean (Standard Deviation) or Total Number (Percentage)

Figure 1: FMT drives changes in host transcriptional profiles.




Figure 2: Gene sets associated with ribosome/protein synthesis and lipid metabolism are altered by FMT.




Figure 3: FMT promotes increased colonic crypt length.




Figure 4: Crypt length is correlated with Myc and mTORc1 target genes.




Figure 5: FMT promotes expression of IL-33 signaling, EGFR ligand, and tissue remodeling genes.




Figure 6: Visual summary of FMT-promoted changes in colonic gene expression.

